Phase Ib/II study of safety and clinical response to Azacitidine and Carboplatin priming for Ipilimumab and Nivolumab re-challenge in patients with advanced melanoma who areresistant to immunotherapy.
Latest Information Update: 16 Nov 2021
At a glance
- Drugs Azacitidine (Primary) ; Carboplatin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRIME005
- 16 Nov 2021 New trial record